These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38969367)

  • 1. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.
    Robledo KP; Lefresne S; Soon YY; Sahgal A; Pinkham MB; Nichol A; Soo RA; Parmar A; Hegi-Johnson F; Doherty M; Solomon BJ; Shultz DB; Tham IW; Sacher AG; Tey J; Leong CN; Koh WY; Huang Y; Ang YLE; Low J; Yong C; Lim MC; Tan AP; Lee CK; Ho C
    BMJ Open; 2024 Jul; 14(7):e078335. PubMed ID: 38969367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From
    Pike LRG; Miao E; Boe LA; Patil T; Imber BS; Myall NJ; Pollom EL; Hui C; Qu V; Langston J; Chiang V; Grant M; Goldberg SB; Palmer JD; Prasad RN; Wang TJC; Lee A; Shu CA; Chen LN; Thomas NJ; Braunstein SE; Kavanagh BD; Camidge DR; Rusthoven CG
    J Clin Oncol; 2024 Oct; 42(30):3606-3617. PubMed ID: 39047224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
    Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M;
    Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
    Yu F; Ni J; Zeng W; Zhou Y; Guo T; Zeng Y; Zhao Y; Li S; Li Y; Yang X; Zou L; Wang S; Liu Q; Li Y; Chu L; Chu X; Ye L; Yu W; Zhu Z
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):804-815. PubMed ID: 34058255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    Wakuda K; Yamaguchi H; Kenmotsu H; Fukuda M; Takeshita M; Suetsugu T; Kirita K; Ebi N; Hataji O; Miura S; Chibana K; Okamoto I; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
    BMC Cancer; 2020 May; 20(1):370. PubMed ID: 32357848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
    Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C
    Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
    Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
    Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis.
    Erickson AW; Brastianos PK; Das S
    JAMA Netw Open; 2020 Mar; 3(3):e201617. PubMed ID: 32211870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
    Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
    J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon
    Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
    Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.
    Zhu Y; Liu C; Xu Z; Zou Z; Xie T; Xing P; Wang L; Li J
    Chin Med J (Engl); 2023 Nov; 136(21):2551-2561. PubMed ID: 37160733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.